SYL 1001

Drug Profile

SYL 1001

Alternative Names: SYL-1001; SYL-1001 DP

Latest Information Update: 19 Apr 2016

Price : $50

At a glance

  • Originator Sylentis
  • Class Analgesics; Eye disorder therapies; Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference; TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes; Ocular pain

Most Recent Events

  • 04 Apr 2016 Sylentis completes a phase II trial for Ocular pain in Spain and Estonia (NCT02455999) prior to April 2016
  • 14 Mar 2016 Interim efficacy and adverse events data from two phase II trials in Ocular pain released by Sylentis
  • 07 May 2015 Sylentis initiates enrolment in a phase II trial for Ocular pain in Spain (EudraCT2014-004857-15)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top